Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Total Liabilities (2022 - 2025)

Historic Total Liabilities for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $58.4 million.

  • NewAmsterdam Pharma's Total Liabilities fell 326.87% to $58.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.4 million, marking a year-over-year decrease of 326.87%. This contributed to the annual value of $107.1 million for FY2024, which is 8247.48% up from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma's Total Liabilities is $58.4 million, which was down 326.87% from $36.6 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Total Liabilities registered a high of $107.1 million during Q4 2024, and its lowest value of -$398.4 million during Q1 2023.
  • For the 4-year period, NewAmsterdam Pharma's Total Liabilities averaged around -$10.9 million, with its median value being $55.8 million (2025).
  • As far as peak fluctuations go, NewAmsterdam Pharma's Total Liabilities surged by 11924.15% in 2024, and later tumbled by 4645.19% in 2025.
  • NewAmsterdam Pharma's Total Liabilities (Quarter) stood at $48.0 million in 2022, then grew by 22.26% to $58.7 million in 2023, then soared by 82.47% to $107.1 million in 2024, then tumbled by 45.52% to $58.4 million in 2025.
  • Its Total Liabilities stands at $58.4 million for Q3 2025, versus $36.6 million for Q2 2025 and $41.0 million for Q1 2025.